BUZZ-Street View: FDA nod for Vertex's oral non-opioid painkiller 'the start of something big'

Reuters2025-01-31
BUZZ-Street View: FDA nod for Vertex's oral non-opioid painkiller 'the start of something big'

** The U.S. Food and Drug Administration on Thursday approved Vertex Pharmaceuticals' VRTX.O drug, branded as Journavx, to treat acute pain, offering a first-of-its-kind alternative to addictive opioid painkillers that have fueled a national crisis

** Shares up 7.39% to $470.8 premarket

PRICING NOT HIGH AS FEARED

** BMO Capital Markets ("outperform", PT: $545) says approval in acute pain sets stage for VRTX's next leg of growth

** Truist Securities ("buy", PT:$460) says price tag of Journavx is certainly higher than generic opioids, but not as high as feared

** Leerink Partners ("outperform", PT: $542) notes the published drug labeling as a best-case scenario, pricing is roughly in line with its expectations

** TD Cowen ("buy", PT: $525) suspects it may take time for Journavx's launch to gain momentum

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment